Watch the video and download the slides


GU NURSES CONNECT Update from ESMO 2021 and EONS14 (English)

GU NURSES CONNECT expert Pablo Peinado has summarised the oncology nursing highlights from ESMO 2021 and the European Oncology Nursing Society (EONS14).

Watch the video and download the slides.

Update from ESMO 2021 including EONS14

Hi, my name is Pablo Peinado. I am a Research Nurse Coordinator at the GU Unit in Virgen De La Victoria Hospital, Málaga, south of Spain.

On behalf of GU Nurses CONNECT I would like to comment some relevant abstracts which have been published presently in ESMO '21 and EONS14.

Which abstracts did you select?

After attending both congresses I selected three different abstracts to present today.

The first one, it's from ESMO '21, and it was presented by Dr. Fizazi. The title, it's "Health-related quality of life, pain and safety outcomes in the phase 3 VISION study of Lutetium-PSMA in patients with metastatic castration-resistant prostate cancer".

The second one, it was presented in EONS14 by Urska Kosir. The title is "Delays in screening and diagnosis of cancer during COVID: What can we expect for the next years?"

And the third and last one was presented in EONS14 by Adeline Duflot. 'It's called "Remote monitoring by Nurses Navigators: From experimentation to optimisation of routine practices".

What are the main conclusions?

The abstract presented by Dr. Fizazi evaluating the pain results, health-related quality of life and safety outcomes in the VISION study, has been very positive. We already know about his positive results in overall survival and radiographic progression-free survival, presented in ASCO. But now they've shown a really positive reduction in the risk of pain deterioration compared to baseline and in the risk of quality of life reduction compared to baseline. Apart from that, it has shown a really positive result as well, with the time to the first skeletal event.

Regarding the abstract presented by Urska, in EONS14, she has exposed how the COVID19 pandemic has reduced both the cancer diagnosis, and the urgent oncological referrals. One of the most affected population have been the young cancer patients, showing an important impact in their mental health, due to diagnostic delays, treatment and virtual attention during the pandemic.

Adeline's presentation explains the remote monitoring by nurses navigator going from experimentation to optimisation of routine practices. This study has shown how the nurses navigators have been able to take autonomous decisions in the majority of cases. This improves the use of resources, reduces the oncologic referrals, and improves the patients attention.

What are your take-home messages from EONS14 at ESMO 2021?

After reviewing those abstracts we see the importance of the nurses inside the multidisciplinary team in both with an oncologic patient. Thanks to the new technologies we can have a more personalised attention for our patients, and improve their quality of life.

It is really important for us, as nurses, to fight for these kind of services that have shown such a high benefit for our patients.

On behalf of GU Nurses CONNECT, thank you very much for watching this video, and remember that you can download the slides.

Pablo Peinado is a Senior Research Nurse Coordinator at Hospital Universitario Virgen de la Victoria in Malaga, Spain.  Pablo gained his Nursing Degree at the University of Valencia in 2014 and moved to the UK where he worked as a surgical nurse for two years.  In 2016 he received his Clinical Trials master’s degree and started to work as a Haematology Research Nurse at Churchill Hospital, Oxford where he was in charge of conducting different clinical trials for haematology patients. Pablo moved back to Spain in 2017 to be part of a new GU tumour unit under Dr David Olmos at Hospital Virgen de la Victoria, Malaga and worked as an Oncology Research Nurse with GU patients diagnosed with prostate, bladder and kidney cancer, coordinating early and late phase clinical trials.  He has recently been promoted to lead a new Clinical Research Unit and is in charge of coordinating a unit where the objectives are to treat patients with the most advanced medications and provide a personalised approach to their disease so that they can participate more actively during their treatment, learning about their disease and understanding the process of their treatment.

GU NURSES CONNECT Update from ESMO 2021 and EONS14 (Español)

GU NURSES CONNECT ha resumido los aspectos más destacados de la enfermería oncológica de la ESMO 2021 y la Sociedad Europea de Enfermería Oncológica (EONS14).

Experts
Pablo Peinado
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.